Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript

SA Transcripts158.63K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call February 25, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor RelationsTodd Watanabe - President, CEO & DirectorL. Edwards - Executive VP & Chief Commercial OfficerPatrick Burnett - Executive VP & Chief Medical OfficerLatha Vairavan - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research DivisionJudah Frommer - Morgan Stanley, Research DivisionUy Ear - Mizuho Securities USA LLC, Research DivisionSerge Belanger - Needham & Company, LLC, Research DivisionJin Law - Goldman Sachs Group, Inc., Research DivisionDouglas Tsao - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc.

Fourth Quarter Fiscal Year 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would like now to turn the conference over to Brian Schoelkopf, Head of Investor Relations. Please go ahead. Brian SchoelkopfHead of Investor Relations Thank you, Michelle. Good afternoon, everyone, and thank you for joining us today to review our fourth quarter and full year 2025 financial results and business update. Slides for today's call are available on the Investors section of the Arcutis' website. Joining me on the call today are Frank Watanabe, President and CEO of Arcutis; Todd Edwards, Chief Commercial Officer; Patrick Burnett, Chief Medical Officer; and Latha Vairavan, Chief Financial Officer. I'd like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand it over to Frank to begin today's call.